Tolerance develops toward GLP-1 receptor agonists' glucose-lowering effect in mice.

Animals Blood Glucose / metabolism Drug Tolerance Exenatide / pharmacology Glucagon-Like Peptide-1 Receptor / agonists Glucose Tolerance Test Hypoglycemic Agents / pharmacology Liraglutide / pharmacology Male Mice Mice, Inbred C57BL
Exenatide GLP-1 receptor agonists Liraglutide

Journal

European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354

Informations de publication

Date de publication:
15 Oct 2020
Historique:
received: 21 06 2020
revised: 29 07 2020
accepted: 29 07 2020
pubmed: 5 8 2020
medline: 19 5 2021
entrez: 5 8 2020
Statut: ppublish

Résumé

Glucagon-like peptide 1 (GLP-1) receptor agonists are popular antidiabetic drugs with potent glucose-lowering effects and low risk of hypoglycemia. Animal experiments and human data indicate that tolerance develops toward at least some of their effects, e.g., gastric motility. Whether tolerance develops toward the glucose-lowering effect of GLP-1 receptor agonists in mice has never been formally tested. The hypothesis of tolerance development in mice will be reported in this study. The direct glucose-lowering effect of the GLP-1 receptor agonists was measured in non-fasted mice and with intraperitoneal glucose tolerance test. Exenatide (10 μg/kg) and liraglutide (600 μg/kg) both substantially lost efficacy during the 18-day treatment as compared to the acute effect. We conclude that our results demonstrate development of tolerance toward GLP-1 receptor agonists' glucose-lowering effect in mice.

Identifiants

DOI: 10.1016/j.ejphar.2020.173443 PMID: 32750365
pubmed: 32750365
pii: S0014-2999(20)30535-5
doi: 10.1016/j.ejphar.2020.173443
pii:
doi:

Substances chimiques

Blood Glucose 0
Glucagon-Like Peptide-1 Receptor 0
Hypoglycemic Agents 0
Liraglutide 839I73S42A
Exenatide 9P1872D4OL

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

173443

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Tuuli Sedman (T)

Department of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, 19 Ravila Street, 50411, Tartu, Estonia; Centre of Excellence for Genomics and Translational Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, 19 Ravila Street, 50411, Tartu, Estonia; Tartu University Hospital, 8 L. Puusepa Street, 51014, Tartu, Estonia.

Maarja Krass (M)

Department of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, 19 Ravila Street, 50411, Tartu, Estonia; Centre of Excellence for Genomics and Translational Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, 19 Ravila Street, 50411, Tartu, Estonia.

Kertu Rünkorg (K)

Department of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, 19 Ravila Street, 50411, Tartu, Estonia; Centre of Excellence for Genomics and Translational Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, 19 Ravila Street, 50411, Tartu, Estonia.

Eero Vasar (E)

Department of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, 19 Ravila Street, 50411, Tartu, Estonia; Centre of Excellence for Genomics and Translational Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, 19 Ravila Street, 50411, Tartu, Estonia.

Vallo Volke (V)

Department of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, 19 Ravila Street, 50411, Tartu, Estonia; Centre of Excellence for Genomics and Translational Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, 19 Ravila Street, 50411, Tartu, Estonia; Tartu University Hospital, 8 L. Puusepa Street, 51014, Tartu, Estonia. Electronic address: vallo.volke@ut.ee.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Tolerance develops toward GLP-1 receptor...
questionsmedicales.fr › Glucides › Sucres › Oses › Hexose › Glucose › Glycémie › Tolerance develops toward GLP-1 receptor...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Tolérance aux médicaments › Tolerance develops toward GLP-1 receptor...
questionsmedicales.fr › Facteurs biologiques › Toxines biologiques › Venins › Exénatide › Tolerance develops toward GLP-1 receptor...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur hormone gastrointestinale › Récepteurs des peptides similaires au glucagon › Récepteur du peptide-1 similaire au glucagon › Tolerance develops toward GLP-1 receptor...
questionsmedicales.fr › Techniques d'investigation › Techniques de laboratoire clinique › Tests de chimie clinique › Analyse chimique du sang › Hyperglycémie provoquée › Tolerance develops toward GLP-1 receptor...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › Tolerance develops toward GLP-1 receptor...
questionsmedicales.fr › Hormones gastrointestinales › Peptides glucagon-like › Glucagon-like peptide 1 › Liraglutide › Tolerance develops toward GLP-1 receptor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Tolerance develops toward GLP-1 receptor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › Tolerance develops toward GLP-1 receptor...